Status:
UNKNOWN
Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Lead Sponsor:
Seoul National University Hospital
Conditions:
High Grade Glioma
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the present study is to assess whether a new method of quantifying therapy-associated hemodynamic alterations based on DCE MR imaging may help to distinguish pseudoprogression from true pro...
Detailed Description
Combination temozolomide and radiation significantly prolongs survival compared with radiation alone and has become standard treatment for glioblastoma multiforme (GBM). Response assessment in GBM is ...
Eligibility Criteria
Inclusion
- Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the patients show the measurable enhancing portion (1 cm in the long diameter according to the RANO criteria) in the immediate f/up MRI after CCRT.
Exclusion
- Among the patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who received concurrent chemoradiation (CCRT) with temozolomide, the patients do not show the measurable enhancing portion (1 cm in the long diameter according to the RANO criteria) in the immediate f/up MRI after CCRT.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT01499823
Start Date
December 1 2011
End Date
December 1 2013
Last Update
December 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Seoul, South Korea, 110-744